Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab). The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.

Trial Details

NCT ID
NCT07732634
Phase
PHASE2
Sponsor
University of Illinois Chicago
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • RiMO-301
  • Pembrolizumab
  • Radiation
  • Surgical resection
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Diagnosis of head and neck cancer that requires surgical resection
  • Must have at least one lesion that is clinically accessible to RiMO-301 injection and amenable to receiving hypofractionated radiotherapy
  • The selected target lesions must be measurable on cross-sectional imaging, and repeated measurements at the same location should be achievable
  • Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection, and with no complic…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →